<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="silico drug repurposing. The SARS-CoV-2 main protease is essential for" exact="viral" post="replication and an attractive drug target. In this study,"/>
 <result pre="screening ISM 1. Introduction An outbreak of the novel coronavirus" exact="disease" post="(COVID-19) in December of 2019 in Wuhan, China, has"/>
 <result pre="attractive drug target due to its essential role in the" exact="viral" post="life cycle, crucial for viral replication. The pp1a and"/>
 <result pre="its essential role in the viral life cycle, crucial for" exact="viral" post="replication. The pp1a and pp1ab, two overlapping polyproteins, important"/>
 <result pre="replication. The pp1a and pp1ab, two overlapping polyproteins, important for" exact="viral" post="replication and transcription, are encoded by the SARS-CoV-2 replicase"/>
 <result pre="one of the best-characterized drug targets among coronaviruses, in the" exact="absence of" post="closely related human homologues, the Mpro represents one of"/>
 <result pre="Materials). 3. Discussion Current prevention and treatment options for SARS-CoV-2" exact="infections" post="are insufficient due to lack of approved drug therapy"/>
 <result pre="Therefore, drug repurposing is a promising therapeutic strategy for many" exact="viral" post="diseases and the most realistic in the present pandemic."/>
 <result pre="reported from studies identifying that ciclesonide inhalant may improve the" exact="respiratory" post="status in severe COVID-19-induced pneumonia [20] and in cases"/>
 <result pre="ciclesonide inhalant may improve the respiratory status in severe COVID-19-induced" exact="pneumonia" post="[20] and in cases of mild- to mid-stage COVID-19"/>
 <result pre="as well as the elderly. It is effective in controlling" exact="chronic" post="inflammation of the respiratory tract and the only steroid"/>
 <result pre="elderly. It is effective in controlling chronic inflammation of the" exact="respiratory" post="tract and the only steroid that showed anti-SARS-CoV-2 activity"/>
 <result pre="evaluate the antiviral effect of ciclesonide on the reduction of" exact="viral" post="load in patients with mild COVID-19 [22]. Raltegravir, the"/>
 <result pre="patients with mild COVID-19 [22]. Raltegravir, the first approved human" exact="immunodeficiency" post="virus type 1 (HIV-1) integrase inhibitor and the best"/>
 <result pre="mild COVID-19 [22]. Raltegravir, the first approved human immunodeficiency virus" exact="type 1" post="(HIV-1) integrase inhibitor and the best Mpro allosteric inhibitor"/>
 <result pre="of tolvaptan therapy was reported in patients with the COVID-19-associated" exact="syndrome" post="of inappropriate antidiuretic hormone secretion [25,26]. In our work,"/>
 <result pre="explain that treatment with ACE-inhibitors is associated with less severe" exact="disease" post="in SARS-CoV-2 infection [31]. A number of drugs selected"/>
 <result pre="with ACE-inhibitors is associated with less severe disease in SARS-CoV-2" exact="infection" post="[31]. A number of drugs selected in our study"/>
 <result pre="types of chemical elements in the compound and N is" exact="total" post="number of atoms. The EIIP signal is then transformed"/>
 <result pre="of a given numerical â€œsignalâ€� series (from a transformed, encoded" exact="primary" post="protein sequence in our case), N is the total"/>
 <result pre="encoded primary protein sequence in our case), N is the" exact="total" post="number of points in this series), n is the"/>
 <result pre="the corresponding binding region in the protein. 4.2. Data Preparation" exact="Protein" post="sequences were downloaded from the UniProt database (https://www.uniprot.org/) with"/>
 <result pre="no conflict of interest. References References 1.collab: World Health OrganizationCoronavirus" exact="Disease" post="2019Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019(accessed on 15 April 2020) 2.YameyG.SchÃ¤ferhoffM.PateM.ChawlaM.RansonK.HatchettR.WilderR.Funding the"/>
 <result pre="of its inhibitorsNature202010.1038/s41586-020-2223-y 8.WuF.ZhaoS.YuB.ChenY.M.WangW.SongZ.G.HuY.TaoZ.W.TianJ.H.PeiY.Y.et al.A new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature202057926526910.1038/s41586-020-2008-332015508 9.AnandK.ZiebuhrJ.WadhwaniP.MestersJ.R.HilgenfeldR.Coronavirus main proteinase (3CLpro) structure: Basis"/>
 <result pre="its inhibitorsNature202010.1038/s41586-020-2223-y 8.WuF.ZhaoS.YuB.ChenY.M.WangW.SongZ.G.HuY.TaoZ.W.TianJ.H.PeiY.Y.et al.A new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature202057926526910.1038/s41586-020-2008-332015508 9.AnandK.ZiebuhrJ.WadhwaniP.MestersJ.R.HilgenfeldR.Coronavirus main proteinase (3CLpro) structure: Basis for"/>
 <result pre="19.MatsuyamaS.KawaseM.NaoN.ShiratoK.UjikeM.KamitaniW.ShimojimaM.FukushiS.The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting" exact="viral" post="NSP15BioRxiv202010.1101/2020.03.11.987016 20.NakajimaK.OgawaF.SakaiK.UchiyamaM.OyamaY.KatoH.TakeuchiI.A Case of Coronavirus Disease 2019 Treated With"/>
 <result pre="RNA replication by targeting viral NSP15BioRxiv202010.1101/2020.03.11.987016 20.NakajimaK.OgawaF.SakaiK.UchiyamaM.OyamaY.KatoH.TakeuchiI.A Case of Coronavirus" exact="Disease" post="2019 Treated With CiclesonideMayo Clinic ProceedingsElsevierRochester, MN, USA202010.1016/j.mayocp.2020.04.007 21.IwabuchiK.YoshieK.KurakamiY.TakahashiK.KatoY.MorishimaT.Therapeutic"/>
 <result pre="https://clinicaltrials.gov/ct2/show/NCT04330586(accessed on 14 July 2020) 23.DongL.HuS.GaoJ.Discovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19)Drug Discov.202014586010.5582/ddt.2020.01012 24.AlyM.O.Molecular Docking Reveals the Potential of"/>
 <result pre="and safety of oral tolvaptan therapy in patients with the" exact="syndrome" post="of inappropriate antidiuretic hormone secretionEur. J. Endocrinol.201116472573210.1530/EJE-10-107821317283 26.YousafZ.Al-ShokriS.D.Al-soubH.MohamedM.F.COVID-19-associated SIADH:"/>
 <result pre="Well Tolerated Drugs That May Inhibit SARSCov-2 3C-like Protease and" exact="Viral" post="RNA-Dependent RNA Polymerase Activities, and May Have Potential to"/>
 <result pre="disease: A systematic review and meta-analysisBMJ Open20199e02677710.1136/bmjopen-2018-026777 30.FangL.KarakiulakisG.RothM.Are patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?Lancet"/>
 <result pre="systematic review and meta-analysisBMJ Open20199e02677710.1136/bmjopen-2018-026777 30.FangL.KarakiulakisG.RothM.Are patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection?Lancet Respir. Med.20208e2110.1016/S2213-2600(20)30116-832171062 31.BeanD.KraljevicZ.SearleT.BendayanR.PicklesA.FolarinA.RoguskiL.NoorK.ShekA.Oâ€™GallagherK.et"/>
 <result pre="Med.20208e2110.1016/S2213-2600(20)30116-832171062 31.BeanD.KraljevicZ.SearleT.BendayanR.PicklesA.FolarinA.RoguskiL.NoorK.ShekA.Oâ€™GallagherK.et al.Treatment with ACE-inhibitors is associated with less severe" exact="disease" post="with SARS-Covid-19 infection in a multi-site UK acute Hospital"/>
 <result pre="with ACE-inhibitors is associated with less severe disease with SARS-Covid-19" exact="infection" post="in a multi-site UK acute Hospital TrustMedrxiv202010.1101/2020.04.07.20056788 32.MahantaS.ChowdhuryP.GogoiN.GoswamiN.BorahD.KumarR.ChetiaD.BorahP.BuragohainA.K.GogoiB.Potential anti-viral"/>
 <result pre="less severe disease with SARS-Covid-19 infection in a multi-site UK" exact="acute" post="Hospital TrustMedrxiv202010.1101/2020.04.07.20056788 32.MahantaS.ChowdhuryP.GogoiN.GoswamiN.BorahD.KumarR.ChetiaD.BorahP.BuragohainA.K.GogoiB.Potential anti-viral activity of approved repurposed drug"/>
 <result pre="in Comparison with Ribavirin, Favipiravir, Oseltamivir and Umifenovir in Coronavirus" exact="Disease" post="2019 (COVID-19) PandemicFavipiravir Oseltamivir Umifenovir Coronavirus Dis.201910.2139/ssrn.3569866 43.VeljkovicV.CosicI.DimitrijevicB.Is it"/>
 <result pre="0.1923 âˆ’5.4 Levetiracetam DB01202 0.1923 âˆ’5.2 Chlorambucil DB00291 0.1923 âˆ’5.2" exact="Vitamin C" post="DB00126 0.1923 âˆ’5.1 Tizanidine DB00697 0.1923 âˆ’5.0 Ifosfamide DB01181"/>
</results>
